Mode
Text Size
Log in / Sign up
N/A N=47 Randomized Prevention

Clinical Investigation of an Improved Two-piece Stoma Product for People Living With a Stoma

Surgical Stomas

Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Leakage Through Coupling Registered at Each Bag Change (Yes/no) — 0.151; 0.237 Proportion of bag changes/participant — p=0.164

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
New 2-piece Coupling (Device); SenSura Mio Click (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Coloplast A/S
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Leakage Through Coupling Registered at Each Bag Change (Yes/no)
0.151; 0.237 0.164
SECONDARY
How Satisfied Are You With the New Coupling?
35; 4 <0.0001 sig
SECONDARY
Would You Consider Using the New Coupling in the Future?
32; 7 <0.0001 sig

Summary

Open-label, randomized, controlled, comparative, cross-over study with 2 test sequences comparing a new 2-piece coupling system with SenSura Mio Click.

Eligibility Criteria

Inclusion Criteria

  • Has given written consent to participate by signing the Informed Consent Signature Form
  • Be at least 18 years of age and have full legal capacity
  • Is able to handle (apply, remove, cut, etc.) the product and do the assessments themselves
  • Has an ileostomy or colostomy with consistent liquid fecal output (for colostomy: 6-7 Bristol stool scale)
  • Currently use SenSura Mio Click 2p Click flat or concave with 50 mm coupling size
  • Have had their ostomy for at least 90 days
  • Be willing to change the bag at least twice per week
  • Is willing and suitable (determined by the Principal Investigator or designee) to use flat or concave 2p open product during the investigation
  • Is willing to use 2p maxi open bags during the investigation

Exclusion Criteria

  • Is currently receiving or have within the past 60 days received radio-and/or chemotherapy
  • Low doses radio- and/or chemotherapy (assessed by Principal Investigator) is allowed for indications other than cancer.
  • Is currently receiving or have within the past 30 days received topical steroid treatment in the peristomal skin area, e.g., lotion or spray
  • Low dose systemic steroid treatment (e.g., inhalation) assessed by the investigator are allowed.
  • Other systemic steroid treatment (e.g., injection or tablet) are not allowed.
  • Is pregnant and/or breast-feeding
  • Have a loop ileostomy
  • Is currently using convex baseplate
  • Has known hypersensitivity towards any of the products used in the investigation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05652010). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search